Shuttle Pharmaceuticals Holdings, INC S-1 registration statements

Shuttle Pharmaceuticals Holdings, Inc. is offering up to 2,229,300 shares of common stock and pre-funded warrants to raise capital, signaling a strategic shift to AI-driven drug discovery following the acquisition of Molecule.ai and the discontinuance of its clinical trials.

Shuttle Pharmaceuticals Holdings, Inc. is registering shares for resale by a selling stockholder following a strategic pivot to AI-driven drug discovery and the discontinuance of its lead clinical program.

Shuttle Pharmaceuticals registered 625,156 shares for resale tied to a November 2025 pre‑funded warrant, adding a potential stock overhang while providing no proceeds to the company.

Shuttle Pharmaceuticals Holdings, Inc. filed an S-1 registration statement for the resale of 1,180,877 shares of common stock by a selling stockholder, stemming from a recent private placement.

Shuttle Pharmaceuticals is launching a public offering of up to 10 million shares of common stock, with pre-funded warrants available as an alternative for certain investors.

Shuttle Pharmaceuticals plans a firm commitment underwritten offering of common stock and pre-funded warrants to advance its cancer treatment pipeline.

Shuttle Pharmaceuticals is registering for resale 1,464,268 shares of common stock underlying convertible notes and 329,461 shares of common stock issuable upon exercise of warrants, all issued in a recent private placement.

Shuttle Pharmaceuticals Holdings seeks to raise capital through a public offering of common stock and warrants to advance its cancer treatment pipeline.

Shuttle Pharmaceuticals plans a public offering of common stock and warrants to raise capital for clinical trials and ongoing operations.

Shuttle Pharmaceuticals Holdings, Inc. is launching a rights offering to raise up to $4.5 million to support its Shuttle Diagnostics subsidiary and for general corporate purposes.